Wang Jianxin, Zhang Guangchen, Sui Yang, Yang Zhuowen, Chu Yinzhu, Tang Hailing, Guo Binbin, Zhang Cong, Wu Changjun
Department of Ultrasound, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Front Genet. 2020 Nov 2;11:578002. doi: 10.3389/fgene.2020.578002. eCollection 2020.
Tumor microenvironment (TME) plays an essential role in the development and metastasis of breast cancer (BC). More studies are needed on the differences and functions of immune components and matrix components. In this study, we calculated the proportion of tumor-infiltrating immune cells (TICs) and the proportion of immune and matrix components of BC patients from The Cancer Genome Atlas (TCGA). We performed Cox regression analysis and constructed protein-protein interaction (PPI) network based on the differentially expressed genes (DEGs) and obtained the most crucial gene . CD52 significantly upregulated and affected the prognosis of BC patients. Gene set enrichment analysis (GSEA) suggested that the genes in the CD52 high-expression group were mainly enriched in immune-related pathways, while those in the CD52 low-expression group were mainly enriched in metabolic pathways. TICs analyses showed that there should be a positive correlation between CD52 expression and CD8+ T cells, activated memory CD4+ T cells, macrophage M1, and Gamma Delta T cells. It indicated that CD52 might be an essential factor in maintaining the immune-dominant position of TME. These results suggest that CD52 might be a potential biomarker for prognosis and provide a new therapeutic target for BC patients.
肿瘤微环境（TME）在乳腺癌（BC）的发生发展和转移过程中起着至关重要的作用。关于免疫成分和基质成分的差异及功能，仍需开展更多研究。在本研究中，我们计算了来自癌症基因组图谱（TCGA）的BC患者肿瘤浸润免疫细胞（TICs）的比例以及免疫和基质成分的比例。我们基于差异表达基因（DEGs）进行了Cox回归分析并构建了蛋白质-蛋白质相互作用（PPI）网络，从而获得了最关键的基因。CD52显著上调并影响BC患者的预后。基因集富集分析（GSEA）表明，CD52高表达组中的基因主要富集于免疫相关途径，而CD52低表达组中的基因主要富集于代谢途径。TICs分析显示，CD52表达与CD8 + T细胞、活化记忆CD4 + T细胞、巨噬细胞M1和γδ T细胞之间应存在正相关。这表明CD52可能是维持TME免疫主导地位的关键因素。这些结果表明，CD52可能是一种潜在的预后生物标志物，并为BC患者提供了新的治疗靶点。
